Methoxydienone
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Identifiers | |
| |
| Synonyms | Methoxygonadiene; 3-Methoxy-17-dehydro-18-methyl-19-nor-δ2,5(10)-testosterone; 13β-Ethyl-3-methoxygona-2,5(10)-dien-17-one; 18-Methyl-19-nor-δ2,5(10)-epiandrosterone 3-methyl ether |
| CAS Number | 2322-77-2 |
| PubChem (CID) | 102242 |
| ChemSpider | 92372 |
| UNII | 12AU99WIMP |
| Chemical and physical data | |
| Formula | C20H28O2 |
| Molar mass | 300.442 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Methoxydienone, also known as methoxygonadiene, as well as 3-methoxy-17-dehydro-18-methyl-19-nor-δ2,5(10)-testosterone or 13β-ethyl-3-methoxygona-2,5(10)-dien-17-one, is a synthetic anabolic-androgenic steroid (AAS) and progestogen of the 19-nortestosterone group related to levonorgestrel which was never marketed.[1] It was synthesized in the 1960s and 1970s by chemist Herchel Smith and his colleagues while they were developing progestins for use in oral contraceptives.[1] The drug is a potent anabolic when administered via injection with an anabolic:androgenic ratio of approximately 54:27 relative to testosterone propionate and 90:625 relative to nandrolone.[1] Methoxydienone is not 17α-alkylated (instead featuring a ketone at the C17 position) and no data exist regarding its oral activity in humans.[1] It has been sold on the Internet as a designer steroid.[1]